Cancer: Drugs

Department of Health written question – answered on 1st March 2017.

Alert me about debates like this

Photo of Pauline Latham Pauline Latham Conservative, Mid Derbyshire

To ask the Secretary of State for Health, pursuant to the Answer of 20 February 2017 to Question 63820, if he will take steps to increase the maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund from two to three years.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

There is no maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund (CDF). The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, the National Institute for Health and Care Excellence and the company concerned. The timeframe will normally be up to two years, but will be considered on a case by case basis.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.